Compare
Semnur Pharmaceuticals, Inc. vs Aspire Biopharma Holdings, Inc. vs Accustem Sciences Inc. vs NeuroSense Therapeutics Ltd.
| Latest fiscal year | Semnur Pharmaceuticals, Inc. SMNR | Aspire Biopharma Holdings, Inc. ASBP | Accustem Sciences Inc. ACUT | NeuroSense Therapeutics Ltd. NRSN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $6.2K | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | -1.9% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$160.42M | -$24.48M | -$1.76M | -$11.12M |
| EPS (Diluted) | -$0.78 | -$16.38 | -$0.12 | -$0.44 |
| Operating cash flow | -$5.87M | -$4.92M | -$850.4K | -$7.67M |
| Free cash flow | n/a | n/a | n/a | -$7.68M |
| Cash & equivalents | $20.0K | n/a | n/a | $166.0K |
| Total assets | $1.35M | $1.31M | $1.55M | $1.03M |
| Total liabilities | $22.10M | $7.69M | $4.95M | $2.59M |
| Shareholders' equity | -$20.75M | -$6.38M | -$3.40M | -$1.56M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 230.21M | 3.53M | 16.07M | 32.56M |
Revenue, most recent five fiscal years
| Fiscal year | Semnur Pharmaceuticals, Inc. | Aspire Biopharma Holdings, Inc. | Accustem Sciences Inc. | NeuroSense Therapeutics Ltd. |
|---|---|---|---|---|
| Latest | n/a | $6.2K Ended 2025-12-31 | n/a | n/a |
| 1 year earlier | n/a | n/a | n/a | n/a |
| 2 years earlier | n/a | n/a | n/a | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |